Displaying 41 (all) recruiting clinical trials.
-
ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors
This study will have two groups of patients to test the combination of AMG 510 (Sotorasib) and panitumumab for advanced cancers with KRAS G12C mutations ...
-
Open-Label Multicenter Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies
This Phase 1, multi-center, open-label, dose escalation study will enroll and treat approximately 120 adult subjects with relapsed/refractory DLBCL NOS (including DLBCL arising from ... -
A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study
This is a Phase 1 study testing whether the new medicine BBO-8520 (a KRASG12C on/off inhibitor) is a safe and effective treatment option if ...
-
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin s Lymphoma
This is a multicenter, open-label Phase 1 study testing a new drug called ARV-393 in adults with advanced non-Hodgkin lymphoma (NHL). The study will look ...
-
A Phase 1a/b Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB-58067 an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 ... -
A Phase 1 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of BL-M07D1 in Subjects with HER2 Expressing Advanced Malignant Solid Tumors
This is a multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of BL-M07D1 in subjects with metastatic or unresectable ... -
A PHASE 0/I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF XRD-0394 IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH HIGH GRADE GLIOMAS
This is an open-label, dose-finding study of XRD-0394 in subjects with newly diagnosed and recurrent high grade gliomas receiving radiation therapy, with and without concurrent ... -
A Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors
This is a Phase 1 study testing the study medicine GSK5733584 (B7-H4 targeted antibody-drug conjugate (ADC )) in patients with advanced solid tumors. The study drug ...
-
A Phase 1 Open-Label Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid ... -
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH BRAF-MUTANT MELANOMA AND OTHER SOLID TUMORS
This is a first-in-human, open-label, Phase 1a/b master protocol to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of PF-07799544 (also ...